HINATURE
PURITO, a leading eco-friendly K-beauty brand by HINATURE Inc., is launching a new sunscreen.
The product to be released is a sunscreen based on chemical filters (SPF 50+ PA++++), which has been tested for its Sun Protection Factor and UVAPF by several testing institutions both in Korea and overseas.
In addition to the high UV protection level, it contains five different types of ceramides that help strengthen the skin barrier and protect it from environmental stressors.
As PURITO strives to offer innovative solutions for environmental sustainability, the brand is launching sunscreen in upcycled sugarcane packaging, and a 100% PCR tube.
The new sunscreen will be launched under the third “Create Me” project initiated on yearly basis by PURITO to allow the brand to create the product together with the customers.
The main features of the products, its core ingredients, texture, finish, and whether it will be fragranced or not were determined through a consumer survey with the help of more than 6000 participants. The package design and the name of the product were selected by the voting system conducted on the official social media channels of the brand.
Ensuring the product reflects the customers’ needs, PURITO is in the final steps of developing the sunscreen with a silky texture and non-oily finish, that does not cause an eye-stinging sensation and does not leave a white cast on the skin. The new sunscreen will have a lightweight texture that will allow smooth application and quick absorption into the skin.
This product is recommended for all skin types, including oily and combination.
About PURITO
PURITO is an eco-friendly K-beauty brand that is known around the world for its great attention to product efficacy and using the highest-quality ingredients.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221226005001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Media Release: Allianz lifts financial ambitions at its Capital Markets Day 202410.12.2024 07:07:00 CET | Press release
Allianz introduces four new ambitious Group financial targets for the 2024-2027 period:Earnings per share CAGR of 7-9 percent1Return on equity of at least 17 percent2Solvency II operating capital generation of 24-25 percentage points in 20273Cumulative net cash remittance of more than 27 billion euros in the years 2025-2027Allianz commits to an attractive total payout ratio of at least 75 percent on average4Having built the foundation to deliver growth at scale, Allianz continues its resilient value creation with three levers: smart growth, reinforced productivity, and strengthened resilienceA flight to trust, accelerated by secular trends, is fuelling greater demand for innovative Protection and Retirement solutions. Through thoughtful portfolio design, Allianz is prepared to capitalize on its role to protect and grow its customers’ most valuable assetsAllianz’s high trust levels and its continued focus on enhancing the customer relationship create a pull effect for Allianz’s products
Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders10.12.2024 05:00:00 CET | Press release
Data presented at American Society of Hematology annual meeting Sirius Therapeutics today announced promising preliminary data from its Phase 1 first-in-human clinical trial of SRSD107, a next generation siRNA therapeutics under clinical development for the prevention and treatment of thromboembolic disorders, such as myocardial infarction, ischemic stroke, and venous thromboembolism. The trial data were presented during a poster session at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held in San Diego, CA. SRSD107 is designed to inhibit Factor XI (FXI), a protein in the coagulation pathway that has shown potential to reduce thrombosis without significantly increasing the risk of bleeding, a major liability of current drugs. “In this trial, SRSD107 was safe and well tolerated, with pharmacokinetic parameters consistent with a typical siRNA product,” said Dr. Patrick Yue, Sirius’ Chief Medical Officer. “We are encouraged by the marked, prolonged reduction
Mori Memorial Foundation Issues GPCI–2024 and GPCI–Financial Centers Reports:10.12.2024 04:00:00 CET | Press release
— Post-Pandemic Economic Recovery and International Tourism Expansion Impact Rankings — The Mori Memorial Foundation’s Institute for Urban Strategies, a research body established by Mori Building, Tokyo’s leading urban landscape developer, today released its Global Power City Index (GPCI) 2024 report on the overall strength of the world’s 48 major cities. For the second time, the report additionally includes the 'GPCI–Financial Centers' index. This index reflects the growing importance of measures taken by major cities to enhance their status as international financial centers, capturing changes in their financial and business environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209714811/en/ The 48 major cities evaluated in Mori Memorial Foundation’s GPCI–2024 Report (Graphic: Business Wire) More than 18 months have elapsed since the World Health Organization declared an end to the COVID-19 pandemic in May 2023.
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets10.12.2024 02:30:00 CET | Press release
5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, further solidifying its position as the leader in new patient starts in both frontline and relapsed/refractory (R/R) CLL with the broadest label of any BTK inhibitorAt a median follow-up of 1.5 years, promising data from the 320 mg expansion cohort of phase 1/1b study shows no progression in patients with treatment-naïve CLL treated with sonrotoclax, a next-generation BCL2 inhibitor, in combination with BRUKINSA highlighting the potential of this fixed-duration, oral-only combination as a best-in-disease optionData for BTK degrader BGB-16673 from phase 1/2 study highlight its potential in both treatment-resistant CLL and other B-cell malignancies representing high unmet needs BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne
Material Receives Splash Award for Outstanding Drupal Website10.12.2024 02:00:00 CET | Press release
– Exceptional client work with INSEAD demonstrates noteworthy innovation and impact in digital engagement solutions – Material, a leading insights, marketing and technology company, is pleased to announce it is the recipient of the Splash Award in the “Education” category for work with INSEAD – The Business School for the World® and runner-up in the “Corporate” category for work with Stuff Limited. The first-ever DrupalCon Singapore Splash Awards celebrate outstanding websites and digital experiences built with Drupal, highlighting the creativity, technical excellence and innovative solutions agencies and developers bring to diverse industries and challenges. For the award-winning “Education” work, Material partnered with INSEAD to enhance the school’s overall digital presence, improve engagement and strengthen brand identity, aligning technology with business strategy to drive growth and success. Leveraging the latest Drupal technology, Material helped INSEAD increase conversion and r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom